Connecting on World MS Day – May 30th 2021

World MS Day takes place on May 30th every year. The 2021-2022 theme of #Connections underscores the importance of building connections to our communities, to ourselves, and to quality care.
Octave Bioscience proudly partnered with Olink Proteomics for an in-depth technical webinar featuring Ferhan Qureshi, VP of Biomarker Product Development at Octave Bioscience, highlighting the importance of creating connections between organizations shaping MS research.
The current standard of care for MS patients relies heavily on assessments that are subjective, qualitative, and inadequate. Octave Bioscience has developed an integrated care platform that consists of several tools to improve measurement capabilities in MS, including: (1) enhanced MRI readings and interpretation, (2) mobile applications, sensors, and wearables to track shifts and changes in symptoms, and (3) a custom assay panel performed using the Olink platform to quantitatively assess the level of disease activity in blood samples.
To develop this panel, Octave screened over 1000 proteins in several deeply phenotyped studies, then associated those biomarkers with clinical and radiographic endpoints.  Octave then used a dynamic and iterative process that balanced statistical, analytical, and biological factors to select proteins for inclusion in the custom panel. The 21-plex panel has been manufactured and analytically validated in preparation for a forthcoming clinical validation in independent cohorts. This informative webinar reviews the research, development, and validation of the custom assay panel.
We are thrilled to welcome Maital Shemesh-Rasmussen to the Octave Bioscience team and we look forward to her leadership, experiences and insights in building out our commercial capabilities and preparing for early deployments. Maital has an abundance of experience in the life sciences and patient-centric healthcare technology fields, as well as deep expertise in strategic marketing and communications, all of which are vital in the positioning and commercialization of Octave’s care management platform.
Shemesh-Rasmussen brings with her an expansive knowledge of leadership in the healthcare technology field, with a proven track record of creating categories, entering new markets, driving market leadership, building world-class teams, and transitioning the promise of novel technology and innovation into market adoption and clinical impact.
Octave Bioscience CEO Bill Hagstrom speaks with Daniel Levine of The Bio Report on Octave’s efforts to harness novel measurements of disease to individualize care, the value for insurance payers, and why Octave is starting with MS.
(The Bio Report)

We welcome Northpond, Deerfield, and Casdin and are thrilled to have them join our existing investors in our shared goal of improving patient lives and outcomes. Neurodegenerative diseases represent a new and important frontier for innovation in the quest to address significant unmet needs and transform care.

“Northpond is excited to lead this investment as we believe Octave’s solution will transform the way neurodegenerative diseases will be managed by providing expanded insights into a patient’s specific disease stage, severity and progression while accessing care protocols and evidence-based insights to improve patient outcomes and quality of life.” -Michael Rubin, MD, PhD, Founder and CEO of Northpond Ventures.
“The key to improved performance is to lower MS disease activity, avoid relapses, slow progression and optimize the drugs now used. As the country’s first true population health precision medicine company, Octave can make a huge impact by providing physicians with the tools, pathways and protocols needed to improve performance. Moreover, programs to improve care coordination, optimize physician networks and deliver higher value case management can provide a major impact at the population level.” -Julian Harris, MD, Partner of Deerfield.
“The introduction of a novel, next-generation objective measurement and management system that will help patients and physicians understand disease trajectory and help to guide therapy decisions is the key to truly personalizing care management for a patient population looking for better answers. From the beginning, we have remained true to our goal of creating a new care model to improve health outcomes and deliver value throughout the entire MS ecosystem.” -Brook Byers, Chairman and founding investor in Octave Bioscience.
(Business Wire)